Tysabri and PML: What Symptoms Should Patients and Doctors Document?
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Specific Risk Communication
If you or a loved one is taking Tysabri and notices new neurological symptoms such as confusion, vision changes, or weakness on one side, it is crucial to understand the signs of progressive multifocal leukoencephalopathy (PML). This concern builds on decades of pharmacovigilance research that has refined how we recognize and manage drug-associated risks. This page reviews the symptoms doctors look for, the diagnostic steps involved, and what the FDA warning means for ongoing monitoring.
Bridging General Warnings to Tysabri-Specific Risks
In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate the timeline between exposure and documented harm, with PML developing after varying durations of therapy. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing JC virus reactivation and replication in the brain. The resulting lytic infection of oligodendrocytes leads to demyelination and the clinical syndrome of PML.
Postmarketing Surveillance and Adverse Event Reports
FDA FAERS adverse-event reports most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, drug ineffective, urinary tract infection, pain, balance disorder, hypoesthesia, pain in extremity, muscular weakness, nasopharyngitis, nausea, dizziness, mobility decreased, stress, cognitive disorder, muscle spasms, depression, and arthralgia (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not listed among the most frequent reports, its occurrence is documented in clinical trials and postmarketing surveillance. In summary, the evidence establishes a clear causal link between Tysabri and PML, with identified risk factors and a documented timeline of harm. The FDA has mandated strong warnings and a restricted distribution program to mitigate this risk. Patients and healthcare providers must weigh the benefits of Tysabri against the risk of PML, considering individual risk factors and monitoring for early signs of the disease.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning about Tysabri and PML?
The FDA requires a boxed warning for Tysabri, stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The warning identifies three risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Healthcare professionals are instructed to monitor patients for symptoms of PML and to withhold Tysabri immediately if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
How does Tysabri cause PML?
Tysabri is an alpha-4 integrin antagonist that inhibits immune cell migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing JC virus reactivation and replication in the brain. The resulting lytic infection of oligodendrocytes leads to demyelination and the clinical syndrome of PML. The risk is higher in patients with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What should I do if I have taken Tysabri and develop symptoms of PML?
If you have taken Tysabri and develop any new or worsening neurological symptoms such as confusion, vision changes, weakness on one side of the body, or difficulty speaking, seek immediate medical attention. Healthcare providers should withhold Tysabri and evaluate for PML. Early diagnosis and management are critical. The TOUCH Prescribing Program ensures that patients and prescribers are informed about the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.